Efficacy of combination therapy versus monotherapy

Breast Cancer Research and Treatment

Volumn 81, Issue SUPPL. 1, 2003, Pages

  Krainer, Michael ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE;

AGE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG RESISTANCE; DRUG RESPONSE; HUMAN; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0344873705     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1026352303876     Document Type: Conference Paper

References (14)

1. Greenspan EM: Results of four drug sequential combination chemotherapy of breast cancer in relation to predominant organ metastases. Proc Ann Meet Am Assoc Cancer Res 6.24, 1965 (abstract)
2. Fossati R, Confalonieri C, Torri V et al.: Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16: 3439-3460, 1998
3. Greenberg PA, Hortobagyi GN, Smith TL et al.: Long-term follow-up of patients with complete remission following combination therapy for metastatic breast cancer. J Clin Oncol 14: 2197-2205, 1996
4. Danesi R, Conte PF, Del Tacca M: Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer. Clin Pharmacokinet 37: 195-211, 1999
5. Gianni L, Munzone E, Capri G et al.: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastaticbreast cancer: high antitumor efficacy and cardiac effects in a dose finding and sequence finding study. J Clin Oncol 13: 2688-2699, 1995
6. Fisherman JS, Cowan KH, Noone M et al.: Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol 14: 774-782, 1996
7. Norris B, Pritchard KI, James K et al.: Phase II comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in dissemated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 18: 2385-2394, 2000
8. Heidemann E, Stoeger H, Souchon R et al.: Balance of time to progression, quality of life, and overall survival: more gain from treatment in single agent treatment with mitoxantrone (N) than with the combination of fluouracil, epirubicin, cyclophosphamide (FEC). Results of a multicenterrandomized trial in high risk metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 19: 74a, 2000
9. Sawada N, Ishikawa T, Fukase Y et al.: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019, 1998
10. O'Shaughnessy J, Miles D, Vukelja S et al.: Superior survival with capecitabine plus doxetacel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-2823, 2002
11. Miles D, Ayoub J-PM, O'Shaugnessy JA et al.: Survival benefit with xeloda (capecitabine)/taxotere (docetaxel) (XT) versus taxotere: analysis of post-study therapy. Breast Cancer Res Treat 69: 287, 2001
12. Sledge GW, Neuberg D, Ingle J et al.: Phase II trial of doxorubicin (A) versus paclitaxel (P) versus doxorubicin + paclitaxel (A+T) as first line therapy for metastatic breast cancer (MBC) an intergroup trial. Proc Annu Meet Am Soc Clin Oncol 17: 1a, 1998
13. Koroleva I, Wojtukiewicz M, Zaluski J et al.: Preliminary results of a phase II randomized trial of taxotere (T) and doxorubicin (A) given in combination or sequentiallly as first line chemotherapy (CT) for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 20: 30a, 2001
14. Joensuu H, Holli K, Heikkinen M et al.: Combination chemotherapy versus single-agent therapy as first-and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 16: 3720-3730, 1998